{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:34:19Z","timestamp":1770899659511,"version":"3.50.1"},"reference-count":36,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1517\/14712598.2014.953048","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T06:53:14Z","timestamp":1409640794000},"page":"1519-1526","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Brentuximab vedotin for treatment of systemic T-cell lymphoma"],"prefix":"10.1517","volume":"14","author":[{"given":"Dai","family":"Chihara","sequence":"first","affiliation":[{"name":"University of Texas, MD Anderson Cancer Center, Department of Lymphoma\/Myeloma","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"University of Texas, MD Anderson Cancer Center, Department of Lymphoma\/Myeloma","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,9,2]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659"},{"key":"e_1_3_2_4_1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow S","year":"2008","unstructured":"Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC), Lyon, France; 2008"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3647"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-310342"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510026200"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","first-page":"abstract 1809","DOI":"10.1182\/blood.V122.21.1809.1809","article-title":"Three-year survival results from an ongoing phase 2 study Of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"122","author":"Pro B","year":"2013","unstructured":"Pro B, Advani RH, Brice P, et al. Three-year survival results from an ongoing phase 2 study Of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2013;122:abstract 1809","journal-title":"Blood"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.069393"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084913"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335216"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185256"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2007.02195.x"},{"issue":"3","key":"e_1_3_2_19_1","first-page":"303","article-title":"Clinicopathological features of adult T-cell leukemia with CD30 antigen expression","volume":"15","author":"Ohtsuka E","year":"1994","unstructured":"Ohtsuka E, Kikuchi H, Nasu M, et al. Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leuk Lymphoma 1994;15(3-4):303-10","journal-title":"Leuk"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376319"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181bf677d"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.7911"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.670216"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462655"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","first-page":"abstract 797","DOI":"10.1182\/blood.V120.21.797.797","article-title":"Brentuximab Vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable cd30 expression","volume":"120","author":"Krathen M","year":"2012","unstructured":"Krathen M, Sundram U, Bashey S, et al. Brentuximab Vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable cd30 expression. Blood 2012;120:abstract 797","journal-title":"Blood"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-533109"},{"key":"e_1_3_2_31_1","first-page":"abstract TPS861","article-title":"Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL)","volume":"31","author":"O\u2019Connor OA","year":"2013","unstructured":"O\u2019Connor OA, Pro B, Illidge T, et al. Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL). J Clin Oncol 2013;31:abstract TPS8611","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1425"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","first-page":"abstract 4380","DOI":"10.1182\/blood.V122.21.4380.4380","article-title":"Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event","volume":"122","author":"Gandhi M","year":"2013","unstructured":"Gandhi M, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood 2013;122:abstract 4380","journal-title":"Blood"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"O\u2019Connor OA Masszi T Savage KJ et al. Belinostat a novel pan-histone deacetylase inhibitor (HDACi) in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): Results from the BELIEF trial [abstract 8507]. ASCO annual meeting abstracts; 2013","DOI":"10.1200\/jco.2013.31.15_suppl.8507"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14712598.2014.953048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:50:02Z","timestamp":1770897002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14712598.2014.953048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,2]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1517\/14712598.2014.953048"],"URL":"https:\/\/doi.org\/10.1517\/14712598.2014.953048","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}